RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
November 3, 2023
RegMed Investors (RMi) Closing Bell: are the unknowns known?
November 2, 2023
RegMed Investors (RMi) Closing Bell: sector rallies … again
November 1, 2023
RegMed Investors (RMi) Closing Bell: Cell and gene therapy sector is still not out of the woods
October 31, 2023
RegMed Investors (RMi) Closing Bell: sector jumps saying good-bye to October
October 27, 2023
RegMed Investors (RMi) Closing Bell: Another trip to the abyss, reason - the economy
October 26, 2023
RegMed Investors (RMi) Closing Bell: market dives, sector thrives
October 25, 2023
RegMed Investors (RMi) Closing Bell: yet another sector share pricing reverse
October 24, 2023
RegMed Investors (RMi) Closing Bell: elevating the oversold with help from “uncle algo”
October 23, 2023
RegMed Investors (RMi) Closing Bell: continued sentiment difficulties with an extreme risk adverse investor psychology
October 20, 2023
RegMed Investors (RMi) Closing Bell: cauterizing a wound after a portfolio whack, almost
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.